{
    "Overall_score": {
        "Correlation": 9,
        "Sentiment": 8,
        "Importance": 8,
        "Impact": 7,
        "Duration": 6,
        "Virality": 4,
        "Source_Score": 7,
        "Specificity": 9,
        "Sector_Spread": 5,
        "Tech_Mentions": 3
    },
    "Each_item": [
        {
            "News_content": "PFE Xalkori (Crizotinib) treatment met the main goal in Phase III trial of untreated patients of lung cancer significantly prolonging PFS",
            "Correlation": 10,
            "Sentiment": 8,
            "Importance": 9,
            "Impact": 8,
            "Duration": 7,
            "Virality": 3,
            "Source_Score": 7,
            "Specificity": 10,
            "Sector_Spread": 4,
            "Tech_Mentions": 2
        },
        {
            "News_content": "Pfizer Inc. PFE XALKORIÂ® Beats Chemo For Previously Untreated Patients In Phase 3 Study",
            "Correlation": 9,
            "Sentiment": 8,
            "Importance": 8,
            "Impact": 7,
            "Duration": 6,
            "Virality": 4,
            "Source_Score": 7,
            "Specificity": 9,
            "Sector_Spread": 5,
            "Tech_Mentions": 2
        },
        {
            "News_content": "GTAT Daily Chart Most recent stock chart and technical analysis.",
            "Correlation": 6,
            "Sentiment": 5,
            "Importance": 4,
            "Impact": 3,
            "Duration": 2,
            "Virality": 2,
            "Source_Score": 6,
            "Specificity": 5,
            "Sector_Spread": 3,
            "Tech_Mentions": 8
        }
    ]
}